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Introduction
Earlier versions of the other articles in this Value in Health
Special Issue, Moving the QALY Forward: Building a Pragmatic
Road (articles 2–6) were presented at an ISPOR Development
Workshop on “Moving the QALY Forward: Building a Prag-
matic Road” held in Philadelphia from November 6–8, 2007.
After the discussion of the articles, a workshop consensus group
was formed, including representation from the groups producing
the other articles. It fell to the consensus group to identify
common ground on key issues.
Given the diversity of views expressed at this workshop, as
evidenced in the articles presented, it was clear that it would not
be possible to reach agreement on speciﬁcs, such as how QALYs
should be measured, or which instrument(s) should be used.
Rather, the group felt that the best way forward was to reach
agreement on several high-level principles and to express dis-
agreements as a set of issues for further research. In all, eight
general statements were agreed upon, which were then put to all
the workshop participants for discussion. These statements are
outlined as follows, along with the main points arising in the
discussion.
Consensus Statements
QALYs Are One Health-Based Input to Health and
Health-Care Decisions
This statement embodies two important points. First, QALYs, as
currently constituted, focus on health as opposed to well-being
more generally. This is the most appropriate focus, given that the
stated objective of most health-care systems is to improve the
health of the population.
Second, the statement recognizes that there are other inputs
to health decisions, which need to be considered alongside
QALYs. These were not speciﬁed in detail, but the existing
literature shows that equity and social justice are salient con-
siderations in the allocation of health-care resources. In the dis-
cussion, it was pointed out that further research was required
into the nature of such considerations and how they should be
incorporated (see Statement 5).
QALYs Can Be Used at Various Levels in the
Health-Care System
It became apparent during the conference that participants felt
that QALYs could potentially inform various types of decisions.
Traditionally, they have been used to inform broad resource
allocation decisions among groups in the population. On the
other hand, some participants felt they could be used to inform
the choice of treatment for individual patients or patient
groups. Within the context of a private health plan, they might
be used to inform decisions about coverage or the levels of
co-payments.
It is important to recognize these various potential uses of
QALYs because this is one source of the disagreement over whose
values should be used in constructing QALYs. For example, the
fact that QALYs are often used for population-wide decisions is
usually cited as a reason for eliciting health state preference
values from members of the general population. On the other
hand, those whose focus is primarily on clinical decisions, involv-
ing different treatments for the same condition, tend to argue that
the most appropriate values are those of patients.
In the discussion, it was pointed out that although there was
some knowledge in the use of QALYs in broad resource alloca-
tion decisions (e.g. National Institute for Health and Clinical
Excellence (NICE) in the UK), little was known about their use in
other decision-making contexts. Therefore, the role of QALYs as
a “multilevel” decision tool should be a priority for research,
perhaps by undertaking case studies and surveys in different
settings. Conference participants noted that in countries where
the government was not the primary funder of health care,
resource allocation decisions occurred in narrower contexts and
there is a need to determine how decision-makers in these settings
would make best use of QALYs.
Health Is a Determinant ofWell-Being
Although the current focus of the QALY, and most health-care
decision-making, is on improvements in health, this statement
acknowledges that the broader objective is to improve well-
being. Although there was not a consensus on the need to widen
the concept of QALYs to encompass all aspects of well-being,
there was recognition of the need to think more expansively
about the impact of health-care interventions and their relation-
ship to other social programs. This is particularly important in
areas such as broad public health interventions, mental health,
and care of the elderly.
In the discussion, it was pointed out that despite statements
about the need for intersectoral initiatives by governments, rela-
tively little is known about the relationship between health and
well-being. Also, little is known about the nonhealth effects of
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health-care interventions, or the health impacts of programs in
social care, education, or environmental protection.
If the aim was to optimize the use of all resources in public
programs, an expanded QALY-type measure of well-being would
clearly be useful. However, this remains a matter for further
research and should not lead us to neglect the use of the QALY
as an important component of current population-based health-
care decision-making.
Both Ex Ante Preferences and Experiences May Count
One of the main discussion points during the workshop was
whether individuals who had not experienced particular health
states could adequately conceptualize them (this discussion
relates back to the Issue Panel debate held at the ISPOR 11th
Annual International Meeting, May 2006).
This issue cannot be separated from those discussed under
Consensus Statement 2, in that members of the general public are
unlikely to have experienced all the health states one might ask
them to value, although they may have friends or family that
have experienced the states concerned. Therefore, it is possible
that some researchers may take the normative view that, for
broad resource allocation decisions, the general population’s
values should count, while at the same time agreeing with the
positive statement that those who have experienced particular
health states can better conceptualize them.
The consensus group noted that there were several unresolved
issues in the measurement of experienced utility. For example, in
studies of utility in patients and disabled people, many subjects
report unwillingness to sacriﬁce any life expectancy to become
well, even though they are experiencing signiﬁcant health prob-
lems. Therefore, although information about these experiences is
important in health-care decision-making, it is not clear how
such information could be expressed in terms of scores on a 0 to
1 utility scale [1].
Nevertheless, this consensus statement recognizes that both
ex ante preferences (held by those who have never experienced a
given health state), as well as the preferences of those that have
experienced it, could be relevant, depending on the decision-
making context and the normative position taken. In some situ-
ations, the two sets of preferences could be combined, in that
members of the general public could be informed about the views
of those who have experienced the health states that are the
subject of valuation.
The consensus group did not discuss how this might be opera-
tionalized, but did note that more research is required into indi-
viduals’ evaluations of their experiences in given health states,
how these relate to community preferences, and how they can be
better used to inform community preferences.
Distributive Issues Need to Be Addressed
A cost-per-QALY ratio indicates the cost-effectiveness of an
intervention. As such, the ratio is a measure of efﬁciency, rather
than of “fairness.” There was extensive discussion at the work-
shop of the challenges raised by the failure of QALYs to
account for distributive concerns (e.g., the relative priority
given to individuals of different levels of current health, and/or
different capacity to beneﬁt in terms of life expectancy or
health-related quality of life.) In decisions about resource allo-
cation across patient groups, concerns for fairness will count
alongside concerns for efﬁciency in the production of health.
Such concerns may cause social resource allocation preferences
to deviate considerably from the ranking that consideration of
costs per QALY would suggest. These concerns have been
raised internationally in all settings where cost-effectiveness
analysis has been studied and/or applied.
The consensus group recognized that there were at least three
ways of addressing distributive issues in using QALYs. First, the
method of QALY estimation may include a distributional com-
ponent in its construction. For example, valuation based on
person trade-off differs from other valuation methods in that it
explicitly addresses choices between groups of individuals suffer-
ing from conditions of differing severity. Both theoretical and
empirical work has illustrated the manner in which distributional
issues can be factored into QALYs using the person trade-off
(PTO) and other methods.
Second, QALYs calculated from valuation systems such as the
visual analog scale (VAS), the time trade-off (TTO), or the stan-
dard gamble (SG) could be weighted in accordance with public
values for distributive justice rather than being equally weighted
as they are at present. The process for generating weights could
be based on research into the preferences of members of the
public, or developed through the use of citizens’ juries. This work
would involve research into which normative factors (e.g., con-
dition severity, capacity to beneﬁt, fair innings) should gain
highest priority in creating distributional weights.
Third, QALYs may be retained as a measure of health pro-
duction and address distributive issues through a deliberative
decision-making process that would accompany the process of
using QALYs for making determinations of resource allocation.
For example, committees deciding on the allocation of health-
care resources could be asked to address given equity objectives
or constraints, as well as considering the incremental cost-
effectiveness ratios of given interventions.
Although the consensus group did not come to a view on the
preferred approach, it did identify some of the key considerations
in the choice. On the one hand, there is a need for transparency.
The more complicated one makes a QALY measure by incorpo-
rating a sophisticated system of QALY weights, the less transpar-
ent it may be. If one of the current obstacles to the use of QALYs
is that decision-makers do not understand them, more compli-
cated formulations might worsen this situation.
On the other hand, the power of quantiﬁcation may mean
that distributional issues are more likely to be taken into account
if they feature, in some way, in the overall calculation of the value
of a health-care intervention. If these issues are merely noted as
something else for the decision-maker to consider alongside the
calculation of value, they may not be adequately considered.
There is a need for research that compares the different
approaches for incorporating distributional issues into the
decision-making process. For example, are decision-makers’ ex
ante views about equity better accommodated by a QALY esti-
mation procedure based on the PTO? Are distributive issues
more likely to be taken into account if they feature in the actual
quantiﬁcation of the total QALYs gained (through an explicit
weighting scheme), as opposed to the accompanying decision-
making process? How feasible is it to develop an appropriate
weighting scheme?
There was broad agreement at the workshop that distribu-
tional justice is central to resource allocation, but given the lack
of empirical data about the approach that would best serve
decision-makers, there was no consensus as to which of these
approaches are superior. At present, the status quo leaves dis-
tributive concerns outside of cost-effectiveness ratios and many
workshop participants regarded maintaining interpretability of
QALYs as a priority. However, there is a vital need to engage the
decision-making community more effectively in determining how
they would like additional distributive information to be incor-
porated into economic evaluations.
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Different Methods for Valuing Health Yield Different
Results and This Needs to Be Better Understood
The various methods for eliciting preferences for health states
embody differences in: 1) health state descriptive systems; and
2) valuation approach (e.g. TTO, SG, VAS, PTO). The process
of describing health is an important prerequisite to establishing
explicit values. Although there are many similarities between
the various descriptive systems, there are also important differ-
ences (for example the omission of social functioning from the
Health Utilities Index (HUI) and of energy/fatigue from the
EQ-5D).
More research is required on the relationship between the
different approaches and their validity. In addition, there is a
need to understand the extent to which the different descriptive
systems and associated value systems are stable over time and
across settings. Also, the translations between the different
descriptive systems need to be explored (see later discussion).
The aim of QALYs is to value interventions and thus gains (or
averted losses) in health. In the conventional QALY approach,
this is done in an indirect manner: one uses healthy people’s ex
ante valuations of health states and takes the difference between
the pre- and the post-intervention value as the value of the gain
(the “subtraction method”). This approach may fail to capture
how individuals value treatment given that they have an illness or
value being sure of receiving treatment in case of future illness.
The valuation of treatment may be less than proportional to the
size of the health effect [1]. Research is required on the issue.
Somewhat similarly, one may question the assumption (implicit
in QALY calculations) of proportionality between the number of
life years gained and value. In this area, as elsewhere, there may
be diminishing marginal utility of goods (here: years).
Health Gains Need to Be Aggregated over Time
The consensus group was aware that the traditional approach for
aggregating health gains over time is rather simplistic; namely,
the value of health states is multiplied by the time spent in each
state. More research is needed on the linearity of preferences over
time and the ways of obtaining the value of pathways or proﬁles.
The group was aware that, in the debate about healthy years
equivalents (HYEs) in the 1980s, it was acknowledged that
HYEs represented a better approach in principle, but was largely
unworkable, particularly in the context of state transition models
for health-care interventions. Therefore, the question is whether
superior, but workable, methods for aggregating health gains
over time can be developed.
A “Reference Method” Is Required for QALYs
The background to this statement was that the consensus group
felt that the QALY had not reached its full potential, certainly in
terms of its adoption by decision-makers. However, given the
current level of disagreement about the preferred approach, the
group considered that a QALY “reference method” that would
inform the “reference case” concept, ﬁrst developed by the US
Panel on Cost-Effectiveness in Health and Medicine [2] is needed
if cost-effectiveness analyses were to be made more comparable
across diseases and interventions. Under the reference case
approach, a standardized approach for estimating QALYs would
be proposed for inclusion in all economic evaluations, without
excluding other approaches. This would facilitate comparability
in economic evaluations without stiﬂing further methodological
development in the estimation of QALYs.
The consensus group felt quite strongly that this step was
needed in order to move the debate on. Otherwise, it would be
likely that workshops like this one would still be taking place 20
years from now. However, the group was not prescriptive about
how a reference method would be arrived at, noting that 1) one
could pick a measure, or proﬁle of measures, and adopt it; 2) one
could develop a “crosswalk” procedure (or translation) between
the most common measures, so that in principle any could be
used [3]; or 3) one could establish a group, consisting of both
methodologists and decision-makers to review the options and to
decide on the best approach.
The consensus group recognized that there were potential
methodological and practical risks in proposing a reference
method. For example, all of the existing measures (e.g. the
EQ-5D, HUI) focus on speciﬁc attributes of health/ill health.
Therefore, if a single measure were chosen, it could bias the
broad allocation of health-care resources in favor of those health-
care interventions that have the largest impact on those particu-
lar attributes. This bias could be minimized by proposing a
reference approach that was based on more than one measure,
but this would be more costly (e.g., in collecting data in primary
studies such as clinical trials). However, despite recognizing these
risks, the consensus group felt that there was no alternative if the
ﬁeld were to move forward.
As one would expect, this consensus statement generated a
good deal of discussion. A few workshop participants were not
convinced that the selection of a reference method was necessary
in order to move the ﬁeld forward. Others felt that, if a reference
approach were to be determined, one should not necessarily be
constrained by having to select from the existing measures, all of
which had their drawbacks. Some felt that it would be prudent to
wait for the results of the existing cross-walk exercises [3] before
taking the next step.
Summary
The consensus statements previously mentioned represent agree-
ment on a number of “high-level” points. Most were accepted by
the majority of participants, although there were a number of
qualiﬁcations. The greatest disagreement was over the last state-
ment, where a few participants felt that they could not sign up to
a process that would generate a reference method for estimating
QALYs at this point in time. There was, however, a substantial
majority in favor of taking this step, which was seen as advancing
the use of QALYs in cost-effectiveness analyses.
The discussions in the consensus group and the subsequent
discussions among all workshop participants generated a list of
research questions. These are summarized in Table 1.
Discussion: IdentifyingWays Forward
Having responded to the consensus statements and generated the
list of research questions, the discussion then turned to some of
the practical issues that would need to be resolved if we were to
move forward with the QALY. Many of these revolved around
current and future health care decision-making on both sides of
the Atlantic. Others related to the operationalization of a “ref-
erence method” for estimating QALYs.
Current Use of QALYs
It was felt that there should be more study of those organizations,
including NICE in the UK, that currently use QALYs [4]. For
example, is there any evidence that this leads to “better” deci-
sions? Do those currently using QALYs think they are adequate
for the task? What else is considered, in decision-making, along-
side the incremental cost-effectiveness ratio (ICER)? What is the
Toward a Consensus on the QALY S33
experience with citizens’ juries in supporting the decision-making
process, such as NICE’s Citizens Council?
Challenges of Using QALYs in Some Settings
It was noted that most of the use of QALYs had been in central-
ized, single-payer, health-care systems like the British National
Health Service. Several participants were unsure about the role of
QALYs in decentralized health-care systems like that existing in
the United States, where the main motivation may not be to
maximize the health of the total population (subject to equity
constraints).
However, other participants pointed out that major payers
(e.g., WellPoint), and large managed care organizations (e.g.,
Kaiser-Permanente) cover a “community” of individuals that is
the size of many European countries. Some of these organizations
had already considered the impacts of therapy on quality of life
in their decision-making processes [5,6]. It was also noted that,
although there has been a resistance to considering cost or cost-
effectiveness in the past, the mood in the United States was
changing, given the growing unaffordability of health care in
both public and private sectors. A readiness to consider limita-
tions in health care has been found both with members of the
public [7] and within decision-making circles [8,9]. It is also
evident in the current discussions about a new US federal initia-
tive in comparative effectiveness research that some parties feel
should include studies of cost-effectiveness [10].
The workshop participants felt that the way forward was: 1)
to explore with decision-makers their interests in and require-
ments for making use of QALYs and economic analyses; 2)
educate them with respect to advantages and limitations of the
method; and 3) conduct case studies in a range of decision-
making settings that would inform methods decisions. The
decision-making matrix reported in an earlier article in this Value
in Health Special Issue would be a useful starting point for
identifying situations where case studies could be conducted.
Developing a Reference Method of Estimating QALYs
Because the majority of workshop participants were in favor of
this, there was some discussion of how best to proceed. First,
under the aegis of which group should this development take
place? Should it be an international effort, led by an organization
such as ISPOR, or would it need to consist of a series of regional
or local efforts, given different decision-makers’ needs and the
different traditions (comparing the United States and Europe) in
the use of particular instruments? Proposed US-based entities
that could lead this effort include: the Agency for Healthcare
Research and Quality, the Institute of Medicine, and the National
Institutes of Health. There was no resolution of this issue.
Secondly, what should be the composition of the group decid-
ing on the reference approach? The general opinion was that it
should be broadly based, including economists, epidemiologists
and decision-makers representing public health, managed care,
employers, and government.
Finally, what should be the time frame? Several participants
felt that if the need for more data was used as an excuse for not
developing a reference method, it may never happen. The con-
sensus was that movement should go forth quickly with the
commitment that any decisions made would be reviewed after a
few years.
Conclusions
The workshop was successful in two respects. First, a broad
range of perspectives on the future of the QALY were discussed.
Secondly, agreement was reached on several high-level principles
and a research agenda was outlined.
Nevertheless, it was not possible to agree on a single way
forward and, given the diversity of opinion, this is hardly sur-
prising. Nevertheless, the majority opinion was that if the QALY
was to gain broader acceptance by decision-makers, something
must be done to move the debate forward. To this end, the
majority opinion was that efforts should be made to develop a
reference method for estimating QALYs. If this does eventually
happen, this workshop will have made a major contribution.
Only time will tell.
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